Ikarian Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Ikarian Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-200,000	Closed	-$13.3M	–	237
2021 Q3	$13.3M	Buy	+200,000	New	+$11.5M	0.94%	25

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Ikarian Capital's ZNTL Position: Q2 2022 in Review

Ikarian Capital sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2022, closing a stake of 202,203 shares — an estimated $9.33M sold.

Ikarian Capital first reported a position in ZNTL in Q3 2021 and held it in 3 quarters. The position peaked at $16.1M in Q4 2021. 122 funds tracked by Wall St. Rank hold ZNTL as of Q2 2022.

Ikarian Capital reported no remaining Zentalis Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Ikarian Capital sold 202,203 Zentalis Pharmaceuticals shares in Q2 2022, an estimated $9.33M.
Ikarian Capital first reported a position in Zentalis Pharmaceuticals in Q3 2021 and held it in 3 quarters.
Ikarian Capital's Zentalis Pharmaceuticals position peaked at $16.1M in Q4 2021.
122 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.